Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Survival: 20.5 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Italy
City/State/Province: Milan
Hospital: Fondazione IRCCS Istituto Nazionale dei Tumori
Journal: Link
Date: 12/2010

This study involved 20 previously untreated metastatic melanoma patients with a median age of 54 years (range of 22-75). Sixty (60) percent of the patients were male.

Patients were given a combination of the biologic therapy bevacizumab (an antibody the blocks a protein involved in cancer cell growth) and the chemotherapy agent fotemustine as a first-line treatment.

The maximum toxicity level reported was of grade 4. Grade 3-4 neutropenia was reported by 50% of the patients and 20% had grade 3-4 hypertension. There was also one case each of pulmonary embolism, serious shortness of breath, and uterine bleeding.

The reported median overall survival was 20.5 months.

One of the authors is employed by Roche, makers of bevacizumab.

Correspondence: Dr. Andrea Anichini; email:

E-mail to a Friend Email Physician More Information